Zealand Pharma A/S (OTCMKTS:ZLDPF) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Zealand Pharma A/S (OTCMKTS:ZLDPF) has earned a consensus rating of “Moderate Buy” from the eight ratings firms that are presently covering the company, MarketBeat Ratings reports. Five research analysts have rated the stock with a hold recommendation and three have given a strong buy recommendation to the company.

A number of equities analysts recently weighed in on ZLDPF shares. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Zealand Pharma A/S in a report on Friday, March 6th. BNP Paribas Exane cut Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Friday, March 6th. Finally, William Blair reaffirmed a “market perform” rating on shares of Zealand Pharma A/S in a report on Friday, March 6th.

Zealand Pharma A/S Stock Performance

OTCMKTS ZLDPF opened at $48.74 on Friday. The stock has a market capitalization of $3.49 billion, a price-to-earnings ratio of 3.62 and a beta of 0.87. Zealand Pharma A/S has a twelve month low of $35.93 and a twelve month high of $83.12. The company has a current ratio of 23.57, a quick ratio of 23.57 and a debt-to-equity ratio of 0.02. The stock has a 50-day moving average of $47.20 and a 200 day moving average of $60.57.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.87) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.37) by $0.50. The company had revenue of $5.33 million during the quarter, compared to analysts’ expectations of $2.81 million. Zealand Pharma A/S had a return on equity of 41.50% and a net margin of 68.82%. Sell-side analysts anticipate that Zealand Pharma A/S will post 2.37 EPS for the current fiscal year.

About Zealand Pharma A/S

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.